References
- Pajonk F-G, Kessler H, Supprian T, Hamzei P, Bach D, Schweickhardt J, Herrmann W, Obeid R, Simons A, Falkai P, Multhaup G, Bayer T A. Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. J Alz Dis 2005; 8: 23–27
- Kessler H, Bayer T A, Bach D, Schneider-Axmann T, Supprian T, Herrmann W, Haber M, Multhaup G, Falkai P, Pajonk F-G. Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. J Neural Transm 2008; 115: 1181–1187
- Bayer T A, Multhaup G. Involvement of amyloid β precursor protein (Aβ PP) modulated copper homeostasis in Alzheimer's disease. J Alz Dis 2005; 8: 201–206
- Thompson K H, Orvig C. Boon and bane of metal ions in medicine. Science 2003; 300: 936–939
- Crouch P J, White A R, Bush A I. The modulation of metal bioavailability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS J 2007; 274: 3775–3783
- Doraiswamy P M, Finefrock A E. Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol 2004; 3: 431–434
- Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 2006; 106: 1995–2044
- Macreadie I G. Copper transport and Alzheimer's disease. Eur Biophys J 2008; 37: 295–300
- Rochet J-C. Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev Mol Med 2007; 9: 1–34
- Kastenholz B, Garfin D E. Medicinal plants: a natural chaperones source for treating neurological disorders. Protein Pept Lett 2009; 16: 116–120